Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among genetic variables, SNPs of CFH, ARMS2, IL-8, TIMP3, SLC16A8, RAD51B, VEGFA and COL8A1 were significantly associated with the risk of AMD in the Italian cohort.
|
29197628 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brolucizumab (Beovu<sup>®</sup>) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion.
|
31768932 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
|
28926846 |
2017 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study findings suggested that the VEGF +936 TT genotype was associated with AMD among Han Chinese patients.
|
23569009 |
2013 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Overexpression of VEGF is implicated in the pathogenesis of both renal cell carcinoma (RCC) and age-related macular degeneration (AMD).
|
28062400 |
2017 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD.
|
29367644 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.
|
25432081 |
2015 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mechanical stress occurs during different stages of AMD and is a possible inducer of VEGF expression in RPE cells.
|
30328441 |
2018 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.
|
18378209 |
2008 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD).
|
30842468 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study described the 2-year real-life outcome of anti-vascular endothelial growth factor treatment of diabetic macular edema and age-related macular degeneration.
|
31617403 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Magnetic nanoparticles conjugated with "RPE cell -MCP-1 antibody -VEGF antibody" compounds for the targeted therapy of age-related macular degeneration: a hypothesis.
|
28546942 |
2017 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis.
|
31132283 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis.
|
28154252 |
2017 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To identify disease-specific cytokine profile differences in the aqueous humor (AH) (other than the vascular endothelial growth factor) between patients with dry and treated wet age-related macular degeneration (AMD) and healthy controls.
|
30157273 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
An ideal drug candidate for both types of AMD is the one which offers significant protection to the retinal cells from oxidative stress and inhibit VEGF release.
|
31317354 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
|
25558172 |
2014 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the secretion of VEGF by HRPE is regulated by MAP kinase pathways, MAP kinase inhibitors may have potential use as therapeutic agents for CNV in AMD.
|
14566975 |
2003 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
|
30301555 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated.
|
19800536 |
2009 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genotypes of 3 polymorphisms in known AMD susceptibility loci (rs1061170 in complement factor H (CFH), rs11200638 in HTRA1 and rs1413711 in VEGF) were determined.
|
24080590 |
2013 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, whether or not VEGF is indeed critical for the pathogenesis of subretinal neovascularization (SRN) in adulthood, which is a serious complication of age-related macular degeneration, has to be further investigated.
|
10849558 |
2000 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
The standard-of-care therapeutics for the treatment of ocular neovascular diseases like wet age-related macular degeneration (AMD) are biologics targeting vascular endothelial growth factor signaling.
|
29193961 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results show the potential systemic effects of anti-VEGF therapy for AMD.
|
27069359 |
2016 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibiting VEGF is the gold standard treatment for neovascular age-related macular degeneration (AMD).
|
28107458 |
2017 |